TUFTS MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $57.5M
- Transactions
- 4,308
- Companies
- 40
- Average per transaction
- $13,353
Who reported the payments
| Merck | $5,271,603 |
| Genentech, Inc. | $4,231,809 |
| AstraZeneca | $3,024,570 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,835,805 |
| Pfizer | $2,105,449 |
| Regeneron | $1,917,159 |
| Takeda Pharmaceutical Company, Limited | $1,824,657 |
| Gilead | $1,658,108 |
| Eli Lilly | $1,644,098 |
| Argenx US, Inc. | $1,543,750 |
| AbbVie | $1,528,779 |
| Janssen Global Services, LLC | $1,400,000 |
| Teleflex LLC | $1,227,700 |
| Janssen Research & Development, LLC | $1,126,673 |
| Modernatx, Inc. | $1,011,769 |
| Novartis | $978,213 |
| Amgen | $963,245 |
| Biogen | $951,747 |
| Boston Scientific | $905,504 |
| Incyte Corporation | $884,759 |
| Sanofi | $810,374 |
| Bayer | $806,815 |
| Johnson & Johnson | $766,868 |
| Janssen Scientific Affairs, LLC | $745,422 |
| Dompe US, Inc. | $674,441 |
| Irhythm Technologies, Inc. | $613,639 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $600,227 |
| Sanofi US Services Inc. | $569,668 |
| Vertex | $510,714 |
| Dompe Farmaceutici S.p.a. | $507,704 |
| Sarepta Therapeutics, Inc. | $506,667 |
| E.r. Squibb & Sons, L.L.C. | $443,352 |
| United Therapeutics Corporation | $432,748 |
| Abiomed | $407,295 |
| Stryker | $401,345 |
| Medtronic | $393,952 |
| EMD Serono, Inc. | $375,000 |
| Astrazeneca UK Limited | $335,225 |
| Sunovion Pharmaceuticals Inc. | $325,000 |
| Alnylam Pharmaceuticals Inc. | $321,608 |